The United States Patent and Trademark Office (USPTO) has granted patent US12582628B2 to Olatec Therapeutics, Inc. The patent, titled "Methods for treating breast cancer," claims a method of treating breast cancer by administering dapansutrile, or a pharmaceutically acceptable solvate thereof. The method optionally includes the co-administration of a checkpoint inhibitor. The patent's effective date is March 24, 2026.

This patent grant is primarily an informational notice for entities involved in pharmaceutical research and development, particularly in oncology. While it does not impose new compliance obligations, it signifies intellectual property protection for a specific therapeutic approach. Companies operating in this space should be aware of this granted patent as it may affect their freedom to operate or potential licensing opportunities related to dapansutrile and its use in combination therapy for breast cancer.